Unità Operativa Complessa Malattie Infettive Universitarie , Siena University Hospital , Italy ; Institute of Clinical Infectious Diseases , Catholic University , Roma , Italy.
Institute of Clinical Infectious Diseases , Catholic University , Roma , Italy.
Open Forum Infect Dis. 2015 Mar 31;2(2):ofv043. doi: 10.1093/ofid/ofv043. eCollection 2015 Apr.
Background. Hepatitis C virus (HCV) genotype 1 is the most prevalent worldwide. Subtype 1a, compared with 1b, shows lower response rates and higher propensity to select for drug resistance to NS3 and selected NS5A and nonnucleoside NS5B inhibitors. Two distinct clades of subtype 1a have been described. Methods. Using Bayesian methodology, we performed a time-scaled phylogeny reconstruction of clade separation and characterized the geographic distribution, phylodynamics, and association with natural resistance variants of NS3 sequences from 362 patients carrying subtype 1a HCV. Results. All sequences segregated in 2 clearly distinct clades. Clade I showed an earlier origin from the common ancestor compared with clade II. Clade I virus was more prevalent in non-European countries, represented mostly by United States, compared with European (75.7% vs 49.3%; P < .001). The prevalence of the natural NS3 variant Q80K, associated with resistance to the macrocyclic protease inhibitor simeprevir, was detected in 51.6% of clade I and 0% of clade II (P < .001); clade I showed a lower genetic barrier for Q80K, whereas no sign of selective pressure at any protease inhibitor resistance-associated codon was detected. Conclusions. Hepatitis C virus subtype 1a clades have a clearly different distribution in Europe and the United States, and the natural resistance mutation Q80K is exclusively associated with clade I.
丙型肝炎病毒(HCV)基因型 1 在全球范围内最为普遍。与 1b 相比,1a 亚型的反应率较低,对 NS3 和选定的 NS5A 和非核苷 NS5B 抑制剂的耐药性更高。已经描述了 1a 亚型的两个不同分支。
我们使用贝叶斯方法对分支分离进行了时间标度系统发育重建,并对来自携带 HCV 1a 亚型的 362 名患者的 NS3 序列的地理分布、系统发育动力学和与天然耐药变异体的关联进行了特征描述。
所有序列均分为 2 个明显不同的分支。与分支 II 相比,分支 I 从共同祖先起源更早。与欧洲相比(75.7%比 49.3%;P<0.001),分支 I 病毒在非欧洲国家更为普遍,主要代表为美国。与大环蛋白酶抑制剂simeprevir 耐药相关的天然 NS3 变异体 Q80K 在分支 I 中的检出率为 51.6%,而分支 II 中则为 0%(P<0.001);分支 I 中 Q80K 的遗传屏障较低,而在任何蛋白酶抑制剂耐药相关密码子均未检测到选择压力的迹象。
HCV 1a 亚型分支在欧洲和美国的分布明显不同,天然耐药突变 Q80K 仅与分支 I 相关。